Previous 10 | Next 10 |
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced today its participation in three upcoming conferences during the month of May. Chris Temple, Vice President of Operations, will be p...
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Care’s (CTTACC) conference, “Cellular Th...
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023 in Clearwat...
Athersys, Inc. (Nasdaq: ATHX) today announced that it has closed its previously announced offering to sell 3,685,000 shares (the “Shares”) of the Company’s common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase 3,68...
2023-04-18 08:30:29 ET China Jo-Jo Drugstores ( CJJD ) -36% . Athersys ( ATHX ) -33% announces $3.7 million registered direct Offering and concurrent private placement. Presto Automation ( PRST ) -20% . Evaxion Biotech ( EVAX ) -20% promis...
2023-04-18 08:22:15 ET Athersys ( NASDAQ: ATHX ) shares fell 33% premarket on Tuesday after the biotechnology company announced a securities offering to raise $3.7M. The company entered into definitive agreements for the purchase and sale of 3,685,000 shares of its com...
Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into definitive agreements for the purchase and sale of 3,685,000 shares (the “Shares”) of the Company’s common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants t...
Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today it will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executi...
2023-04-03 00:26:33 ET Athersys press release ( NASDAQ: ATHX ): Q4 GAAP EPS of -$0.83 beats by $53.17 . Revenue of $0.1M (-86.1% Y/Y). Net cash used in operating activities was $59.0M in 2022 compared to $76.2M in 2021. As of December 31, 2022, Athersys had $9....
Athersys, Inc. (NASDAQ: ATHX) today announced financial results for the three and 12 months ended December 31, 2022, and provided a business update. Fourth Quarter 2022 and Recent Corporate and Operational Highlights Largely completed the company’s restructuring initiative wi...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...